Compare Cassava Sciences Inc (FLNA) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Hasbro, Inc. — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Hasbro, Inc. trades at $81.92 (market cap $11.39B). The key difference: Hasbro, Inc. is far larger — about 214.3× Cassava Sciences Inc's market cap, and Hasbro, Inc. pays a 3.48% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | HAS | |
|---|---|---|
Market Cap | $53.14M | $11.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $105.88 |
52-Week Low | $1.09 | $70.95 |
Enterprise Value | -$33.43M | $13.66B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Hasbro (HAS) trades at $78.42, down 1.4% on the day, with technical indicators showing a bearish trend while fundamentals reveal mixed signals. The company reported a net loss of $322.4M in 2025 despite beating earnings expectations for three consecutive quarters, with revenue of $4.7B and negative profit margins. Analyst consensus remains strongly positive with a $105.43 price target and no sell ratings among 33 analysts, though technical signals and recent stock performance suggest near-term pressure.
The investment case hinges on execution of Hasbro's 'aging up' strategy and Wizards segment growth against significant debt levels and profitability challenges. While Wall Street sees 34% upside to consensus targets, investors face risks from competitive pressures, high valuation multiples, and inconsistent earnings performance that could limit near-term appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
